Intec Pharma enters agreement with Michael J. Fox Foundation
Intec Pharma announces it has entered into an agreement with the Michael J. Fox Foundation for Parkinson's Research to support patient recruitment and retention support for the Intec Pharma's pivotal Phase III clinical trial of its lead product candidate, the Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, which began enrolling participants in April, 2016. MJFF is the largest non-profit funder of Parkinson's research with a mission to accelerate the development of new therapies and a cure for Parkinson's disease. Previously, the foundation supported Intec Pharma with a $705,000 grant to fund a pre-clinical study of AP-CD/LD.